Natco Pharma's Kothur unit classified as 'voluntary action indicated' by US regulator
Natco Pharma Ltd announced that its Kothur unit in Hyderabad received an Establishment Inspection Report (EIR) from the US FDA, classifying the facility as 'Voluntary Action Indicated' (VAI). The US FDA had previously conducted an inspection of th...
The US Food and Drug Administration (FDA) had conducted an inspection at the company's pharma division located in Kothur, Hyderabad, Natco Pharma said in a regulatory filing.
The unit has now received Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated (VAI)", it added.
Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or recommend regulatory action, as per the USFDA.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.